Skip to main content

Table 2 Occurrence of most common imbalances in different epithelial neoplasias by CGH

From: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data

Regional imbalance Most frequent* Above background Putative targets**
occuring in most carcinoma types
Breast, ovary, HCC, cervix, NPC, MEL, endometrial, vulva Gastric, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, SQS ABL2, ETV3
dim(3p) HNSCC, NSCLC, cervix, ES, RCC, NE, MEL (whole chr. 3), SCLC, vulva, SQS Gastric, PAC FHIT, MLH1
maxima at 3q26q27 (except 3q25 in NPC)
Ovary, HNSCC, NSCLC, cervix, ES, NPC, SCLC, endometrial, vulva, SQS Gastric, RCC, PAC BCL6, PIK3CA
frequently whole chromosome
Ovary, HCC, NSCLC, cervix, ES, bladder, cholangio, SCLC Gastric, CRC, HNSCC, RCC, PAC, PRDM5
enh(5p) Thyroid, NSCLC, cervix, Gastric, ovary, CRC, HCC, HNSCC, ES, bladder, NE, PAC, cholangio, vulva CDH6, TERT
dim(5q) Ovary, NSCLC, Prostate, gastric, HNSCC, ES, bladder, cholangio, APC, MCC
enh(6p) HCC, MEL Ovary, NSCLC, cervix, ES, bladder, cholangio, SCLC, vulva E2F3, ID4
maxima at 6q16q21 or 6q24q27
Prostate, RCC, MEL Ovary, HCC, NSCLC, cervix, bladder, NE, PAC, cholangio, SCLC CCNC
frequently whole 7, mostly max. on 7q
Prostate, thyroid, ES, RCC Gastric, ovary, CRC, HCC, HNSCC, bladder, MEL, PAC (7p>7q), cholangio (7p>7q) 7p: EGFR 7q: ABCB1, MET
dim(8p) Breast, prostate, CRC, HCC Ovary, HNSCC, NSCLC, ES, RCC, bladder, PAC, SCLC, vulva DLC1, MSR1, N33
ubiquitously high (exception NE and thyroid)
Breast, prostate, ovary, CRC, HCC, HNSCC, NSCLC, ES, RCC, bladder, MEL, PAC, cholangio, endometrial, vulva Cervix, NPC, SCLC, SQS MYC
9p or whole 9
frequently distinct (high-level) gain
HNSCC Breast, gastric, ovary, NSCLC, ES, NPC, bladder, MEL, PAC, cholangio CCND1, FGF3
dim(11q23qter) NPC, NE, vulva Breast, HNSCC, cervix, ES, MEL, SCLC ATM (11q22), (LOH11CR2 A, TSG11)
frequently whole 12; slight max. on 12p
NPC Ovary, CRC, HNSCC, NSCLC, ES, RCC, PAC, vulva 12p: CDK2, CDK4, GLI, KRAS 12q: MDM2
mostly 13q14q21
Prostate, HCC, thyroid, bladder, NE, PAC, SCLC, endometrial Breast, gastric, ovary, HNSCC, NSCLC, cervix, ES, RCC, NPC (max. at 13q31), MEL, CRC, vulva BRCA2, RB1, STARD13
dim(16q) Breast, NPC Prostate, gastric, HCC, SCLC CDH1, ATBF1
dim(17p) Breast, gastric, CRC, cholangio, SCLC Ovary, HCC, NSCLC, cervix, ES, RCC, NPC, bladder, PAC, SQS TP53
enh(17q) Breast, gastric, bladder, NE, PAC, cholangio, SCLC, SQS HCC, HNSCC, NSCLC, cervix, ES, renal, NPC ERBB2
dim(18q) Gastric, ovary, CRC, HNSCC, PAC, SQS HCC, NSCLC, cervix, renal, bladder, cholangio DCC, SMAD4
enh(19q) NE, SCLC Breast, CRC, PAC, vulva AKT2, BAX
enh(20q) Gastric, CRC, thyroid, bladder, NE, PAC, cholangio Breast, HCC, cervix, ES, renal, MEL, SCLC, vulva STK15/AuroraA
  1. Please refer to table 1 for abbreviations. * "most frequent" lists entities in which the aberration belongs to the 3 most frequent imbalances of the specified quality (enh = gain, dim = loss; bold if most frequent change in entity). Entities are sorted according to the total number of included cases. Chromosomal regions 1p, 21, 22, X and Y were omitted due to differences in reporting (e.g. exclusion of regions prone to errors in chromosomal CGH analysis). ** Listed are some examples of genes with oncogene (for gain regions) or tumor suppressor (for loss regions) function. However, a large number of possible target genes as well as structural features may exist for each region.